^
HER-2 1899‐1G>A
Gastric Adenocarcinoma
trastuzumab
Resistant
:
C4
The Oncologist - 2wk
No biomarker
Gastric Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A1
PD-L1 expression
Gastric Adenocarcinoma
pembrolizumab
Sensitive
:
A2
HER-2 overexpression
Gastric Adenocarcinoma
trastuzumab
Sensitive
:
A2
MET expression
Gastric Adenocarcinoma
AMG 102
Resistant
:
B
MET amplification
Gastric Adenocarcinoma
AMG 102
Resistant
:
B
HER-2 positive
Gastric Adenocarcinoma
pembrolizumab + margetuximab
Sensitive
:
C2
CLDN18.2 expression
Gastric Adenocarcinoma
IMAB362
Sensitive
:
C2
HER-2 amplification
Gastric Adenocarcinoma
trastuzumab + avelumab
Sensitive
:
C2
MET amplification
Gastric Adenocarcinoma
crizotinib
Sensitive
:
C3
PD-L1 expression
Gastric Adenocarcinoma
pembrolizumab + margetuximab
Sensitive
:
C3
ATM mutation
Gastric Adenocarcinoma
Immunotherapy
Sensitive
:
C3
ATR mutation
Gastric Adenocarcinoma
Immunotherapy
Sensitive
:
C3
ATRX mutation
Gastric Adenocarcinoma
Immunotherapy
Sensitive
:
C3
PD-L1 underexpression
Gastric Adenocarcinoma
toripalimab + surufatinib
Sensitive
:
C3
HER-2 amplification
Gastric Adenocarcinoma
HER2 inhibitor
Resistant
:
C3
Chr amplification(11)(q13)
Gastric Adenocarcinoma
Immunotherapy
Resistant
:
C3
MDM2 amplification
Gastric Adenocarcinoma
Immunotherapy
Resistant
:
C3
MDM4 amplification
Gastric Adenocarcinoma
Immunotherapy
Resistant
:
C3
CDKN2A deletion
Gastric Adenocarcinoma
Immunotherapy
Resistant
:
C3
CDKN2B deletion
Gastric Adenocarcinoma
Immunotherapy
Resistant
:
C3
PD-L1 expression
Gastric Adenocarcinoma
PD-L1 inhibitor
Sensitive
:
C3
MET amplification
Gastric Adenocarcinoma
RG3638
Sensitive
:
C4
FGFR2 amplification
Gastric Adenocarcinoma
TAS 120
Sensitive
:
D
FGFR2 amplification
Gastric Adenocarcinoma
nintedanib
Sensitive
:
D
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our